{ "$schema_version": "5.4", "review_mode": "fresh", "claim_restatement": { "index_wording": "Epitalon activates telomerase and extends human healthspan", "entry_form": "conjunction", "gradeable_restatement": "In humans, administration of the synthetic tetrapeptide Epitalon activates telomerase in somatic cells, produces durable telomere maintenance with net elongation, and thereby slows age-related functional decline sufficiently to extend healthspan.", "restatement_required": true, "split_into": [ "SC1: telomerase activation", "SC2: in-vivo human telomere consequence", "SC3: human healthspan effect", "SC4: telomerase mediation", "SC5: net human benefit" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "In humans", "determinable_before_outcome": true, "determined_from": "species and enrollment status", "action": "retained" }, { "qualifier": "synthetic tetrapeptide Epitalon", "determinable_before_outcome": true, "determined_from": "intervention identity and sequence Ala-Glu-Asp-Gly", "action": "retained" }, { "qualifier": "chemically defined material", "determinable_before_outcome": true, "determined_from": "identity and purity of the administered or applied peptide", "action": "retained, with the limitation recorded that no cited study reports independent verification of the identity or purity of the material used" } ] }, "lay_summary": { "paragraphs": [ "The claim says that the synthetic four-amino-acid peptide Epitalon turns on telomerase, the enzyme that can maintain chromosome ends, and that this molecular effect helps people remain healthy for longer.", "The review assigns Γ, meaning mechanistically plausible with partial system support. Two research groups report telomerase or chromosome-end effects in cultured human cells, a third reports a similar effect in cattle cells, and several animal studies report mixed longevity findings. No study shows telomerase activation after the peptide is given to people, and no trial of the synthetic peptide measures human healthspan.", "Confidence in that grade is low, which in this framework is a statement about the evidence rather than about the conclusion: the literature is small, nearly all of it comes from one group of connected laboratories, two of the animal reports could only be read in summary, and the one independent laboratory study had all three of its main figures replaced after publication. The missing evidence is a controlled human study linking molecular target engagement to durable functional benefit. The grade describes the present causal evidence and does not determine whether future trials will succeed." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C3", "C6", "C9", "C10", "C13", "C18" ], "jargon_glossed": [ "telomerase: an enzyme that can maintain chromosome ends", "healthspan: time lived with preserved health and function" ], "no_practical_advice": true, "written_for": "general reader, no field background" }, "hypothesis": { "name": "Epitalon-telomerase human healthspan hypothesis", "central_claim": "Synthetic Epitalon activates telomerase in humans and thereby extends human healthspan.", "proposed_mechanism": "Epitalon induces telomerase, preserves or elongates telomeres in human somatic tissues, and slows functional aging through that telomere-dependent effect.", "claimed_scope": "universal", "claimed_level": [ "progression" ], "is_conjunctive": true, "conjunctive_note": "The claim joins molecular target engagement, an in-vivo telomere consequence, human functional benefit, and mediation; no study has isolated the complete chain." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [ "03-epigenetics-gene-regulation.md" ], "index_notes_applied": [ "No index entry exists for this hypothesis; the metabolism-and-aging rubric governs healthspan, biomarker, developmental, and lifespan distinctions.", "A stub index entry is recommended in redteam/SYNTHESIS_CHANGE_LOG.md so future reviews inherit the product-identity rule and the scope reasoning applied here." ], "rubric_fit_note": "Routing was re-checked against every rubric in the packet. 06-metabolism-aging remains primary: the claimed endpoint is human healthspan. 03-epigenetics-gene-regulation is added as a secondary rubric governing the proposed proximal step, in which the tetrapeptide binds DNA and/or linker histone and activates transcription of the telomerase catalytic subunit; that rubric places sequence-motif evidence in its Weak tier and its Δ threshold requires an endogenous perturbation with demonstrated specificity against global transcriptional or cell-cycle collapse plus a matched rescue, none of which exists for this peptide. Both rubrics return a Γ ceiling, so the cross-field lowest-ceiling rule leaves the level unchanged and the second ceiling is recorded rather than assumed. 02-cancer-biology was considered for the alternative-lengthening-of-telomeres finding in cancer lines and rejected as a governing rubric: that result is used here as safety-relevant context, not as a subclaim." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Epitalon directly activates telomerase in human somatic cells.", "subclaim_type": "mechanism", "governing_rubric": "06-metabolism-aging.md; 03-epigenetics-gene-regulation.md ", "claimed_scope": "cultured human somatic cells", "scope": "Cell culture. Direct telomerase activity in prospectively specified human somatic cells. Target engagement after administration to a living person is a separate scope and is carried by SC2.", "key_evidence_anchor": "Independent direct telomerase-activity assays after controlled exposure, followed by demonstration of target engagement after human administration.", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Universal in-vitro ceiling at Γ; rubric-03 Γ cap on the proximal gene-regulation step.", "rationale": "Two independent laboratories report telomerase or telomere effects in cultured human cells and a third independent laboratory reports a telomerase-linked effect in cultured bovine cells. No study demonstrates telomerase activation after administration to a living person. The independent 2025 human-cell report required replacement of all three core data figures by a published erratum, and the proposed proximal binding step rests on a sequence-complementarity model and reported binding, which is the weakest tier of the epigenetics rubric." }, { "id": "SC2", "statement": "Epitalon administration durably maintains or lengthens telomeres in living humans.", "subclaim_type": "generalization", "governing_rubric": "06-metabolism-aging.md", "claimed_scope": "living humans receiving identified synthetic Epitalon", "scope": "Longitudinal telomere change in a prospectively sampled human tissue after confirmed synthetic-Epitalon administration, beyond assay error and cell-composition shifts.", "key_evidence_anchor": "Randomized longitudinal human intervention with tissue-appropriate telomere measurement and telomerase target engagement.", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "In-vitro and biomarker-only evidence cannot exceed Γ for the organism-level inference.", "rationale": "Cultured-cell telomere responses provide partial-system support. No human intervention measures telomerase target engagement together with durable in-vivo telomere preservation, and no independent laboratory has produced any organism-level result. Confidence is Low on the framework's criteria: a small literature, concentrated in one connected research network, with reproducibility concerns in the assays that carry it." }, { "id": "SC3", "statement": "Synthetic Epitalon extends human healthspan.", "subclaim_type": "sufficiency", "governing_rubric": "06-metabolism-aging.md", "claimed_scope": "human age-related function and morbidity", "scope": "Prespecified functional, morbidity, disability-free-survival, or validated multidomain aging endpoints in controlled human intervention studies.", "key_evidence_anchor": "Randomized or comparably controlled human trial with a validated healthspan endpoint and adequate follow-up.", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "The Δ threshold requires an intervention changing lifespan or healthspan; biomarker-only improvement is capped at Γ.", "rationale": "Human reports measure melatonin, clock-gene expression, an undefined condition rating, or disease-specific vision rather than healthspan. Animal survival results are mixed and context-dependent: null on mean lifespan and slightly unfavourable on median in the most auditable mouse study, dose-independent and developmental in the fly, and confined to circadian-disrupted groups in the rat. No evidence exists at the claimed human scope; the level is carried entirely by cell-culture and animal systems." }, { "id": "SC4", "statement": "Any human healthspan effect of Epitalon is materially mediated by telomerase activation and telomere maintenance.", "subclaim_type": "mechanism", "governing_rubric": "06-metabolism-aging.md", "claimed_scope": "causal mediation in humans", "scope": "Within-study linkage of human telomerase target engagement, durable telomere change, and a validated healthspan endpoint, with alternative pathways tested.", "key_evidence_anchor": "Human mediation design or matched perturbation and rescue showing that loss of telomerase engagement abolishes the functional effect.", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "Cross-system mechanism stitching and biomarker confirmation cannot cross Δ.", "rationale": "No human study measures the molecular target and a healthspan endpoint in one causal chain, and no study in any system reports a telomerase blockade, matched rescue or inactive-analogue control for this peptide. Circadian, neuroendocrine and antioxidant routes remain viable alternatives, and an independent 2025 study reports a functional cellular effect of the peptide with no telomerase measurement at all." }, { "id": "SC5", "statement": "Synthetic Epitalon produces a favorable net human healthspan effect over a duration relevant to aging.", "subclaim_type": "generalization", "governing_rubric": "06-metabolism-aging.md", "claimed_scope": "net benefit in humans over long follow-up", "scope": "Systematically ascertained serious adverse outcomes and healthspan benefits in humans exposed to synthetic Epitalon of documented identity and purity.", "key_evidence_anchor": "Adequately powered long-term human safety and efficacy follow-up with pharmacokinetic and product-identity controls.", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "Small biomarker and disease-specific studies provide only partial-system exposure evidence and cannot establish net organismal benefit.", "rationale": "Available human reports are small and provide no pharmacokinetics and no systematic long-term safety ascertainment, which the 2026 regulatory evaluation states explicitly. Animal tumour data from one research network are favourable or null, telomerase activation by gene therapy in old mice did not increase cancer, and the one independent cell study reports raised alternative-lengthening-of-telomeres activity in breast-cancer lines. Human genetic evidence links longer telomeres to higher risk of several cancers and lower risk of some non-neoplastic diseases, so net benefit is a substantive open question rather than a corollary." } ], "aggregation_rule": "weakest-link", "aggregation_preregistered": true, "aggregation_rationale": "The original statement is conjunctive, so cell-level target engagement cannot substitute for human functional benefit and a functional signal cannot substitute for telomerase mediation.", "primary_subclaim_id": "", "aggregation_derivation": "SC1=Γ, SC2=Γ, SC3=Γ, SC4=Γ, and SC5=Γ; weakest-link therefore returns Γ. The letter is the same for every subclaim, which conceals two facts stated in the prose: at the claimed human scope the evidence is empty, and Γ is reached because simplified-system evidence exists in cultured cells and three animal species.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "All three rules return Γ, so aggregation choice does not create a rung swing. The red-team pass argued that the four human-scoped subclaims should sit at Α, on the ground that nothing supports them at their own scope, and rejected it: Α describes a claim sustained by analogy rather than causal evidence, whereas this corpus contains direct interventions with survival endpoints in three species and direct molecular readouts in human cells. The concentration of that work in one research network is recorded in the confidence band, not in the letter." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Context-limited cellular telomere response", "core_claim": "Epitalon can alter telomerase or telomere biology in some proliferating cultured cells without an established organism-level healthspan effect.", "explains_what_nominal_does_not": "It accommodates positive cell assays in three independent laboratories, the internal negative controls that map where those effects stop, absent human target-engagement data, and mixed organismal survival results, without assuming translation.", "strongest_supporting_evidence": [ "Khavinson et al. 2003 [1]", "Al-Dulaimi et al. 2025, corrected [3]", "Ullah et al. 2025, independent bovine laboratory [15]" ], "strongest_contradictory_evidence": [ "No direct contradiction within the cell-culture scope; the main uncertainty is reproducibility across primary tissues and exposure conditions." ], "hsef_level_for_this_model": "Γ", "rationale": "The two laboratories provide direct but simplified-system perturbation evidence. The model makes no unsupported claim about human target engagement or healthspan and therefore best fits the observed boundary." }, { "rank_in_tournament": 2, "model_id": "M1", "is_nominal": true, "name": "Telomerase-mediated human geroprotection", "core_claim": "Epitalon activates telomerase after human administration, maintains telomeres, and thereby extends healthspan.", "explains_what_nominal_does_not": "As the nominal model, it integrates the proposed molecular, cellular, and organismal sequence if every link proves true.", "strongest_supporting_evidence": [ "Direct cell-culture telomerase findings [1,3]", "Reported animal survival signals [4-8]", "Telomerase activation by gene therapy extends median lifespan in old mice with no excess cancer, an effect abolished by a catalytically inactive enzyme [18]" ], "strongest_contradictory_evidence": [ "No human telomerase or telomere target-engagement study [9-11]", "No synthetic-Epitalon human healthspan endpoint [9-11]", "No mean-lifespan benefit and a slightly lower median in SHR mice despite a tail-survival signal [6]", "Rat survival signals confined to circadian-disrupted lighting groups [8,13]" ], "hsef_level_for_this_model": "Γ", "rationale": "The model is plausible and has partial-system support, and the mechanism class it names has been shown to be modifiable with organism-level benefit in old mice by another modality. Its own defining human causal chain has not been tested, and no study shows that this peptide engages that pathway in any living animal, so it remains below the first field-valid healthspan threshold." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Non-telomerase pleiotropic effect (circadian, neuroendocrine, antioxidant)", "core_claim": "The peptide may alter melatonin, clock-gene, oxidative-stress or senescence-marker physiology without telomerase mediating a human healthspan effect.", "explains_what_nominal_does_not": "It explains the available human melatonin and circadian-gene findings without requiring unmeasured telomere target engagement.", "strongest_supporting_evidence": [ "Korkushko et al. 2007 [9]", "Ivko et al. 2020 [10]", "Gatta et al. 2025: AEDG restored wound healing in high-glucose-injured human retinal pigment epithelium through antioxidant and epithelial-mesenchymal-transition-related action, with no telomerase measurement [16]", "Reported binding to methylated DNA and linker histone, which would be expected to act beyond one promoter [3,14]" ], "strongest_contradictory_evidence": [ "The small studies do not establish validated functional outcomes or long-term physiological consequences." ], "hsef_level_for_this_model": "Γ", "rationale": "Human interventions provide limited biomarker support for this alternative and an independent 2025 cell study supplies a functional readout that does not involve telomerase at all. Biomarker-only findings and weak outcome ascertainment still prevent a causal healthspan inference, so the model sits at the same ceiling as the nominal." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Assay or research-program artifact", "core_claim": "The apparent molecular, animal, and clinical signals reflect assay sensitivity, selective analysis, context dependence, or correlated bias rather than a reproducible geroprotective action.", "explains_what_nominal_does_not": "It accounts for concentration of positive organismal reports in one research network, mixed survival outcomes, sparse design detail, and the correction of core figures in the independent cell paper.", "strongest_supporting_evidence": [ "Published erratum replacing all three core data figures in Al-Dulaimi et al. 2025 [3]", "Developmental-only fly exposure with an explicitly dose-independent effect across orders of magnitude [4]", "Null mean and slightly lower median lifespan in SHR mice [6]", "Rat signals present only under disrupted lighting [8,13]" ], "strongest_contradictory_evidence": [ "Two independent laboratories reported telomerase or telomere responses in cultured human cells [1,3], and a third reported a telomerase-linked effect in bovine cells [15]." ], "hsef_level_for_this_model": "Β", "rationale": "A complete-artifact explanation remains possible but is less economical after three laboratories outside and inside the originating network reported bounded cellular effects. The erratum on the independent study is a figure-handling correction by its own authors rather than an expression of concern, and its corrected numbers are the ones used here. The model remains a material explanation for the broader longevity narrative." } ], "tournament_summary": "The shared evidence most strongly favours a context-limited cell response. The nominal human geroprotection model ranks second because its defining in-vivo target engagement, healthspan endpoint and mediation link are untested for this peptide, even though the mechanism class it invokes has organism-level support from telomerase gene therapy in old mice. The non-telomerase model gained support since the prior edition.", "study_separating_rank1_from_rank2": "A blinded randomized older-adult trial measuring in-vivo telomerase target engagement, durable tissue-specific telomere change, and a prespecified validated healthspan endpoint, with mediation analysis.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Khavinson, Bondarev, and Butyugov 2003, Bulletin of Experimental Biology and Medicine", "source_pointer": "PMID 12937682; DOI 10.1023/A:1025493705728", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "In telomerase-negative human fetal lung fibroblast culture, peptide exposure was followed by induction of the telomerase catalytic subunit, telomerase enzymatic activity and telomere elongation.", "what_it_does_not_show": "It does not demonstrate target engagement after human administration, durable in-vivo telomere maintenance, or healthspan.", "confounders_present": [ "single fetal cell culture", "sparsely reported experiment", "no organismal endpoint", "primary available only as a non-machine-readable scan, so the arbitrary-unit values reported in the prior edition could not be re-verified and were withdrawn" ], "verification": "verified", "verification_note": "PubMed record and abstract re-resolved; the cited primary PDF is an image-only scan and yielded no extractable text, so this pass records abstract-and-metadata depth.", "source_tier": "A" }, { "citation": "Khavinson et al. 2004, Bulletin of Experimental Biology and Medicine", "source_pointer": "PMID 15455129; DOI 10.1023/B:BEBM.0000038164.49947.8C", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "The same fetal fibroblast program reported extended passage capacity and preserved telomere length with peptide exposure.", "what_it_does_not_show": "It is not an independent laboratory line and does not establish organismal aging benefit.", "confounders_present": [ "same research program and cell context as the foundational report", "cell-culture selection", "no healthspan endpoint" ], "verification": "verified", "verification_note": "Publisher abstract and article metadata read.", "source_tier": "A" }, { "citation": "Al-Dulaimi et al. 2025, Biogerontology", "source_pointer": "PMID 40908429; DOI 10.1007/s10522-025-10315-x", "relates_to_subclaims": [ "SC1", "SC2", "SC5" ], "favors_models": [ "M1", "M2", "M4" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "An independent laboratory reported longer telomeres and increased telomerase activity after prolonged exposure in normal fibroblast and epithelial cell lines, with different responses in cancer lines.", "what_it_does_not_show": "It does not establish exposure, efficacy, or safety in living people; all three core figures were later corrected.", "confounders_present": [ "two-dimensional cell culture", "few cell lines", "average telomere-length assay", "core-figure correction" ], "verification": "verified", "verification_note": "Complete PMC full text and complete correction notice read.", "source_tier": "A" }, { "citation": "Khavinson et al. 2000, Mechanisms of Ageing and Development", "source_pointer": "PMID 11087911; DOI 10.1016/S0047-6374(00)00217-7", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Weak", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Developmental exposure of Canton-S Drosophila was followed by reported adult mean-lifespan increases.", "what_it_does_not_show": "Because exposure occurred from egg to larva, it does not separate developmental effects from a true intervention on aging and does not establish human healthspan.", "confounders_present": [ "developmental-only exposure", "single strain", "no dose-response", "same originating research network" ], "verification": "verified", "verification_note": "Primary abstract, methods, and accessible results excerpts read.", "source_tier": "A" }, { "citation": "Anisimov et al. 2001, Rossiiskii Fiziologicheskii Zhurnal", "source_pointer": "PMID 11227856", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The English abstract reports lifespan and aging-marker benefits in female CBA mice treated from six months of age.", "what_it_does_not_show": "The inaccessible Russian full text prevents an audit of exact survival effects, allocation, censoring, and healthspan measures, and the result cannot establish a human effect.", "confounders_present": [ "single strain and sex", "abstract-only verification", "same originating research network" ], "verification": "verified", "verification_note": "PubMed English abstract and metadata read; no abstract-external number used.", "source_tier": "A" }, { "citation": "Anisimov et al. 2003, Biogerontology", "source_pointer": "PMID 14501183; DOI 10.1023/A:1025114230714", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "In female outbred SHR mice, the peptide did not change mean lifespan and was associated with a lower median, while the mean lifespan of the last ten per cent of survivors and the maximum lifespan were higher; total tumour incidence was unchanged, leukaemia was six-fold less frequent, and bone-marrow chromosome aberrations were reduced.", "what_it_does_not_show": "It does not show whole-cohort lifespan extension, validated healthspan, telomerase mediation, or human benefit.", "confounders_present": [ "young-adult treatment start", "tail-survival emphasis despite null mean and lower median", "single sex", "treated mice consumed more food from the fifth to the sixteenth month with no body-weight difference", "same originating research network" ], "verification": "verified", "verification_note": "Complete primary PDF re-read; survival table, food-consumption table, tumour table and chromosome-aberration results checked against the prose. The prior edition's median direction was reversed and is corrected.", "source_tier": "A" }, { "citation": "Anisimov et al. 2005, Voprosy Onkologii", "source_pointer": "PMID 15909815", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The English abstract reports benefits in the longest-lived fraction of senescence-accelerated mice without a tumor-frequency effect.", "what_it_does_not_show": "It does not clearly establish a whole-group mean survival benefit, telomerase mediation, healthspan, or translation to humans.", "confounders_present": [ "strain-specific aging model", "abstract-only verification", "tail-survival emphasis", "same originating research network" ], "verification": "verified", "verification_note": "PubMed English abstract and metadata read; no abstract-external number used.", "source_tier": "A" }, { "citation": "Vinogradova et al. 2008, Bulletin of Experimental Biology and Medicine", "source_pointer": "PMID 19110597; DOI 10.1007/s10517-008-0121-7", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "In male rats under standard, natural and constant illumination, mean lifespan was virtually unchanged; population ageing rate and mortality-rate doubling time were normalised in the naturally-lit and constantly-lit groups, and spontaneous tumours were inhibited under every photoregimen.", "what_it_does_not_show": "It does not demonstrate a robust context-independent aging effect, human healthspan, or telomerase mediation.", "confounders_present": [ "effect present only in circadian-disrupted lighting groups", "treatment from young adulthood", "single sex", "same originating research network", "no constant-darkness survival arm exists in this study, contrary to the prior edition" ], "verification": "verified", "verification_note": "PubMed record and abstract re-resolved; the cited primary PDF is an image-only scan. The companion female-rat study was added to supply the maximum-lifespan figures.", "source_tier": "A" }, { "citation": "Korkushko et al. 2007, Advances in Gerontology", "source_pointer": "PMID 17969590", "relates_to_subclaims": [ "SC3", "SC4", "SC5" ], "favors_models": [ "M3" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "In elderly people with pineal functional insufficiency, pineal peptide preparations were reported to raise night melatonin; the report covers the heterogeneous pineal extract and the synthetic tetrapeptide together and the accessible record does not separate their results.", "what_it_does_not_show": "It measured a circadian biomarker, not telomerase, telomeres, healthspan, or long-term safety.", "confounders_present": [ "two different preparations reported together", "allocation, blinding, duration and sample size not stated in the accessible record", "biomarker endpoint", "safety ascertainment not described" ], "verification": "verified", "verification_note": "PubMed record and abstract re-resolved; the primary is an image-only scan. The 2026 regulatory evaluation states that route, dosing, duration, subject numbers, demographics and safety-collection methods are not available. The prior edition's randomisation, placebo and ten-day-course specifics are withdrawn.", "source_tier": "A" }, { "citation": "Ivko et al. 2020, Advances in Gerontology", "source_pointer": "PMID 33280326", "relates_to_subclaims": [ "SC3", "SC4", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "In women with low melatonin, a short AEDG intervention was associated with urinary melatonin-metabolite and clock-gene changes and an inadequately defined condition rating.", "what_it_does_not_show": "It does not establish validated healthspan, telomerase engagement, durable telomere change, or systematic safety.", "confounders_present": [ "small selected sample", "blinding not specified", "undefined subjective outcome", "short follow-up", "biomarker endpoints" ], "verification": "verified", "verification_note": "PubMed record and abstract re-resolved; the design (seventy-five women, a comparison group with age-appropriate metabolite excretion, forty with low excretion allocated twenty per arm, twenty days, blinding unspecified) is taken from the 2026 regulatory evaluation's synthesis of the primary Russian text and is attributed to it in the prose.", "source_tier": "A" }, { "citation": "Khavinson et al. 2002, Neuro Endocrinology Letters", "source_pointer": "PMID 12195242", "relates_to_subclaims": [ "SC3", "SC4", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A retinitis-pigmentosa report describes disease-specific visual improvement after local Epitalon administration.", "what_it_does_not_show": "The study does not measure aging, healthspan, telomerase, telomeres, or long-term systemic safety, and its allocation and blinding are unclear.", "confounders_present": [ "disease-specific local treatment", "unclear randomization and blinding", "active conventional-therapy comparator", "no aging endpoint" ], "verification": "verified", "verification_note": "Primary abstract and accessible scanned primary article text read.", "source_tier": "A" }, { "citation": "Khavinson and Morozov 2003, Neuro Endocrinology Letters", "source_pointer": "PMID 14523363", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Long-term mortality claims in this report concern Epithalamin and Thymalin preparations, not the synthetic tetrapeptide Epitalon.", "what_it_does_not_show": "It cannot establish efficacy, mechanism, or safety for chemically defined synthetic Epitalon.", "confounders_present": [ "different biological preparation", "co-intervention", "older non-contemporary trial methods" ], "verification": "verified", "verification_note": "Complete primary PDF and intervention descriptions read.", "source_tier": "A" }, { "citation": "Vinogradova et al. 2007, Bulletin of Experimental Biology and Medicine", "source_pointer": "PMID 18856211; DOI 10.1007/s10517-007-0441-z", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "In female rats, the peptide did not change lifespan under a standard day-night regimen; maximum lifespan and the mean lifespan of the last ten per cent were prolonged only in the naturally-lit and constantly-lit groups.", "what_it_does_not_show": "It does not show a context-independent ageing effect, human healthspan, or telomerase mediation.", "confounders_present": [ "benefit confined to circadian-disrupted lighting", "treatment from young adulthood", "single sex", "same originating research network" ], "verification": "verified", "verification_note": "PubMed record and abstract read; supplies the verifiable illumination boundary that the prior edition misattributed.", "source_tier": "A" }, { "citation": "Khavinson, Shataeva and Chernova 2005, Neuro Endocrinology Letters", "source_pointer": "PMID 15990728", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Weak", "system": "in silico", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A sequence-complementarity model identifies a base-pair block as the peptide's binding site and reports that the block and its reverse complement occur repeatedly in the telomerase promoter region.", "what_it_does_not_show": "It does not demonstrate binding in cells, promoter occupancy, transcriptional dependence, or specificity against global effects.", "confounders_present": [ "informatics model without endogenous perturbation", "motif occurrence is the weakest tier of the epigenetics rubric", "same originating research network" ], "verification": "verified", "verification_note": "PubMed record and abstract read; routes the proximal mechanism to rubric 03.", "source_tier": "A" }, { "citation": "Ullah et al. 2025, Life Sciences", "source_pointer": "PMID 39788414; DOI 10.1016/j.lfs.2025.123381", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "An independent laboratory reports that peptide-associated telomerase activation improved bovine oocyte maturation and post-thaw blastocyst hatching and implantation potential, with supporting reactive-oxygen-species and mitochondrial-membrane measurements.", "what_it_does_not_show": "It is cultured non-human material used for embryo production; it says nothing about human ageing, healthspan or in-vivo target engagement.", "confounders_present": [ "non-human species", "reproductive rather than ageing endpoint", "cell culture" ], "verification": "verified", "verification_note": "PubMed record and abstract read; a third independent laboratory reporting a telomerase-linked effect.", "source_tier": "A" }, { "citation": "Gatta et al. 2025, Stem Cell Reviews and Reports", "source_pointer": "PMID 40493162; DOI 10.1007/s12015-025-10911-x", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M3" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "In high-glucose-injured human retinal pigment epithelial cells, AEDG restored delayed wound healing by inhibiting hyperglycaemia-induced epithelial-mesenchymal transition and fibrosis, attributed to antioxidant action.", "what_it_does_not_show": "Telomerase and telomeres were not measured, so it supports a non-telomerase route rather than the nominal mechanism, and it is a cell-culture disease model, not ageing.", "confounders_present": [ "cell culture", "disease-specific injury model", "no telomerase readout", "co-authored with the originating institute" ], "verification": "verified", "verification_note": "PubMed record and abstract read.", "source_tier": "A" }, { "citation": "Araj et al. 2025, International Journal of Molecular Sciences", "source_pointer": "PMID 40141333; DOI 10.3390/ijms26062691", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Weak", "system": "review", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "An independent overview records that the peptide has been studied in vitro, in vivo and in silico, that its reported effects are attributed to several partly non-specific mechanisms, and that its physico-chemical and structural characterisation remains limited.", "what_it_does_not_show": "A review frames evidence and carries no experimental result of its own.", "confounders_present": [ "narrative review", "no primary data" ], "verification": "verified", "verification_note": "PubMed record and abstract read; cited for framing and for the characterisation gap, never for a number.", "source_tier": "B" }, { "citation": "Bernardes de Jesus et al. 2012, EMBO Molecular Medicine", "source_pointer": "PMID 22585399; DOI 10.1002/emmm.201200245", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Vector-delivered mouse TERT given to one- and two-year-old mice improved several healthspan measures and increased median lifespan, without increasing cancer relative to littermates; a catalytically inactive enzyme produced none of the benefits.", "what_it_does_not_show": "It is a different intervention in a different species and does not show that this peptide engages telomerase in any living animal; overexpression evidence is capped at Γ for claims about the endogenous pathway.", "confounders_present": [ "gene-therapy overexpression rather than a small molecule or peptide", "single species", "no bearing on the identity of the peptide's target" ], "verification": "verified", "verification_note": "PubMed record and abstract read; supplies the mechanism class's organism-level benchmark and the inactive-enzyme control design.", "source_tier": "A" }, { "citation": "Haycock et al. 2017, JAMA Oncology (Telomeres Mendelian Randomization Collaboration)", "source_pointer": "PMID 28241208; DOI 10.1001/jamaoncol.2016.5945", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human genetic", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Across thirty-five cancers and forty-eight non-neoplastic diseases, genetically higher telomere length was associated with higher odds of several site-specific cancers and lower odds of some non-neoplastic diseases including coronary heart disease.", "what_it_does_not_show": "It concerns lifelong germline-determined telomere length, not pharmacological lengthening in an adult, and it is association-based, so universal cap 2 bars it from raising any subclaim.", "confounders_present": [ "exposure is germline variation, not an intervention", "instrument validity assumptions", "direction of effect differs by outcome" ], "verification": "verified", "verification_note": "PubMed record and abstract read; odds ratios and confidence intervals taken verbatim.", "source_tier": "A" }, { "citation": "Codd et al. 2021, Nature Genetics", "source_pointer": "PMID 34611362; DOI 10.1038/s41588-021-00944-6", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human genetic", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "In a large cohort, genetically determined differences in leukocyte telomere length were associated with multiple traits and diseases, and shorter length at age forty was associated with lower life expectancy than longer length.", "what_it_does_not_show": "It does not show that lengthening telomeres in an adult improves healthspan, and it is association-based.", "confounders_present": [ "exposure is germline variation, not an intervention", "single cohort", "life-expectancy estimate is modelled" ], "verification": "verified", "verification_note": "PubMed record and abstract read.", "source_tier": "A" }, { "citation": "Ivko et al. 2024, Advances in Gerontology", "source_pointer": "PMID 39742404", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M3" ], "evidence_class": "Weak", "system": "review", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A review from the originating institute reports that the peptide regulates circadian genes and markers including a telomere-repeat binding factor, prohibitin and sirtuins in buccal epithelium.", "what_it_does_not_show": "Whether the underlying studies administered the peptide to people or applied it to cultured cells cannot be determined from the accessible abstract; no telomerase activity or telomere length measurement is reported.", "confounders_present": [ "Russian-language review, abstract only", "same originating research network", "marker-level endpoints" ], "verification": "verified", "verification_note": "PubMed record and abstract read; bounds the absence claim and is flagged as an open issue for a future pass.", "source_tier": "A" }, { "citation": "Willis and Vu 2026, International Journal of Pharmaceutical Compounding", "source_pointer": "PMID 42752426", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Weak", "system": "regulatory analysis", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "A peer-reviewed analysis of compounding advisory committee recommendations lists this peptide among synthetic peptides promoted for healthy ageing and sets out the concerns raised in review.", "what_it_does_not_show": "It is policy analysis and carries no causal evidence about the hypothesis.", "confounders_present": [ "not a primary study", "regulatory rather than scientific scope" ], "verification": "verified", "verification_note": "PubMed record and abstract read; corroborates the regulatory context artifact, which itself carries no identifier.", "source_tier": "B" } ], "verification_summary": { "load_bearing_claims_checked": 21, "verified": 21, "unverified": 0, "contradicted": 0, "note": "Every identifier in the prior edition was re-resolved in the red-team pass and each pointed to exactly the paper cited; ten verified references were added. Every numeric claim was re-checked against an opened record. Two primaries are image-only scans: specifics that only those scans supported were withdrawn, and one number taken from an independently hosted primary PDF was corrected for direction. One design description is attributed in the prose to a regulatory synthesis rather than to the primary text." }, "factual_issues_found": [ { "quoted_text": "Epitalon activates telomerase and extends human healthspan", "problem": "The wording joins an in-vitro molecular effect to an untested in-vivo human target-engagement claim and an unmeasured human healthspan outcome.", "source_says": "The direct telomerase evidence is from cultured human cells; the identified synthetic-Epitalon human interventions measured melatonin, clock-gene, subjective, or disease-specific outcomes rather than telomerase and healthspan.", "source_pointer": "PMID 12937682; PMID 40908429; PMID 17969590; PMID 33280326; PMID 12195242", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "This would suggest that epitalon can be safely used in healthy individuals to maintain telomeres and thereby influence the aging process.", "problem": "The safety and human-aging inference exceeds the study design.", "source_says": "The study used a few human cell lines in two-dimensional culture and explicitly identifies that in-vitro design as its main limitation.", "source_pointer": "PMID 40908429; DOI 10.1007/s10522-025-10315-x", "affects_score": false, "action": "logged" }, { "quoted_text": "Peptides of pineal gland and thymus prolong human life.", "problem": "This title is sometimes treated as direct human evidence for Epitalon, but the interventions were Epithalamin and Thymalin, chemically different preparations.", "source_says": "The long-term human report administered pineal and thymic extracts rather than the synthetic Ala-Glu-Asp-Gly tetrapeptide.", "source_pointer": "PMID 14523363", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "In this article, the wrong figures appeared in Figs. 1, 2 and 3.", "problem": "All three core data figures in the 2025 independent cell study were replaced after publication.", "source_says": "The correction provides corrected versions of Figures 1, 2, and 3 and states that the original article has been corrected; it is not a retraction.", "source_pointer": "PMID 41240216; DOI 10.1007/s10522-025-10326-8", "affects_score": true, "action": "logged" }, { "quoted_text": "median lifespan was 512 versus 487 days", "problem": "The prior edition reported the median lifespan as favouring treatment, and transposed the two mean values.", "source_says": "In the primary survival table the control median is 512 days and the treated median 487 days, and the control mean is 456 plus or minus 29 days against a treated mean of 455 plus or minus 31; the favourable signals are confined to the last ten per cent of survivors and the maximum.", "source_pointer": "PMID 14501183; DOI 10.1023/A:1025114230714", "affects_score": false, "action": "corrected" }, { "quoted_text": "maximum-lifespan extension was limited to constant darkness", "problem": "A boundary condition was attributed to a study that contains no constant-darkness arm, and the attribution inverts the reported pattern.", "source_says": "The cited male-rat study used standard, natural and permanent illumination and reports normalisation of ageing rate in the naturally- and constantly-lit groups; its female-rat companion reports no lifespan change under the standard regimen and maximum-lifespan prolongation only under natural and constant light.", "source_pointer": "PMID 19110597; PMID 18856211", "affects_score": false, "action": "corrected" }, { "quoted_text": "The reported mean signal was 240 arbitrary units in treated cells and 180 in untreated controls, a 33.3% difference.", "problem": "A numeric claim rested on a primary available only as a non-machine-readable scan and could not be re-verified in the red-team pass.", "source_says": "The abstract supports induction of the telomerase catalytic subunit, telomerase activity and telomere elongation in telomerase-negative human fetal fibroblast culture, and reports no arbitrary-unit values.", "source_pointer": "PMID 12937682; DOI 10.1023/A:1025493705728", "affects_score": false, "action": "withdrawn" }, { "quoted_text": "randomized older participants to pineal-peptide or placebo groups", "problem": "Design specifics including randomisation, a placebo arm and a ten-day course are not supported by any accessible source, and the study reports two different preparations together.", "source_says": "The abstract states that pineal peptide preparations, the heterogeneous extract and the synthetic tetrapeptide, restored night melatonin release in elderly people with pineal insufficiency; it states no allocation, duration or sample size. The 2026 regulatory evaluation records that route, dosing, duration, subject numbers, demographics and safety-collection methods are not available.", "source_pointer": "PMID 17969590", "affects_score": false, "action": "withdrawn" } ], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ. No exceptions.", "specific_trigger": "Direct telomerase activation has been demonstrated only in cultured human cells, not after administration to living humans.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Telomere changes are confined to cell culture; no longitudinal human intervention measures durable in-vivo telomere preservation.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Biomarker-only improvement without organismal benefit", "specific_trigger": "Synthetic-Epitalon human studies report biomarkers or disease-specific outcomes and no validated healthspan endpoint.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "In vitro reconstitution, biochemistry, cell-free assays, and purified-system work demonstrate plausibility, not endogenous causality.", "specific_trigger": "The telomerase result and the organismal results come from different systems with no mediation or rescue test joining them.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "A hypothesis cannot score highly merely because it changes biomarkers or acute physiology.", "specific_trigger": "Short small studies with sparse adverse-event ascertainment cannot establish long-term net human healthspan benefit.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus in vitro reconstitution or simplified cellular support caps at Γ", "specific_trigger": "The proposed proximal step, in which the peptide binds DNA or linker histone and activates transcription of the telomerase catalytic subunit, rests on a sequence-complementarity model and reported binding; the epigenetics rubric places motif evidence in its Weak tier and no endogenous perturbation with specificity and rescue exists.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Animal pharmacologic interventions can cross the aging rubric's Δ threshold within a model, while single-species and developmental evidence cannot support the claimed human scope above Γ.", "subclaim_scope_cap_binds_on": "SC3 and SC4 at the human healthspan and human mediation scope.", "subclaim_scope_threshold_binds_on": "Animal lifespan subclaims within their tested strain, sex, developmental stage, and illumination context.", "resolution": "Animal intervention results are recorded as organism-level evidence in their own systems; the universal and rubric Γ caps control the inference to human healthspan and telomerase mediation.", "note": "No animal result is promoted into human field-valid causality." }, { "collision": "Two rubrics govern different steps of the same subclaim: the metabolism-and-aging rubric governs the claimed healthspan endpoint, while the epigenetics rubric governs the proximal gene-regulation step.", "subclaim_scope_cap_binds_on": "SC1 at the cultured-human-cell scope, under both rubrics.", "subclaim_scope_threshold_binds_on": "Neither rubric's Δ threshold is satisfied at any scope.", "resolution": "Under the cross-field rule the lowest ceiling governs. Both rubrics return Γ, so routing does not change the letter and the second ceiling is recorded explicitly rather than assumed.", "note": "Recorded so that a future pass cannot read the single-rubric routing of the prior edition as a finding that only one rubric applies." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Khavinson et al. 2003 [1]; Al-Dulaimi et al. 2025 [3]", "gamma_hard_rules_triggered": [ "In vitro evidence alone cannot exceed Γ" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "yes", "perturbation_result_note": "The molecular perturbation is positive in cell culture but has no human in-vivo target-engagement or healthspan endpoint.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Khavinson et al. 2003 [1]; Al-Dulaimi et al. 2025 [3]", "gamma_hard_rules_triggered": [ "Biomarker change without functional/phenotypic change caps at Γ" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "yes", "perturbation_result_note": "Telomere-length changes are positive in selected cell systems but untested in living humans.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Human interventions [9-11] contain no healthspan endpoint.", "gamma_hard_rules_triggered": [ "Biomarker-only improvement without organismal benefit", "Single-species or single-strain evidence cannot establish the human scope" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "no", "perturbation_result_note": "No human healthspan perturbation was identified; animal survival signals are mixed and scope-limited.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Lifespan and/or healthspan extension with mechanistic specificity", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "No study links sources [1 or 3] to a human endpoint in sources [9-11].", "gamma_hard_rules_triggered": [ "In vitro evidence alone cannot exceed Γ", "Biomarker-only improvement without organismal benefit" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "no", "perturbation_result_note": "No telomerase-pathway necessity, rescue, or human mediation test exists.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "Strong alignment of lifespan/healthspan outcomes", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Korkushko et al. 2007 [9]; Ivko et al. 2020 [10]; Khavinson et al. 2002 [11]", "gamma_hard_rules_triggered": [ "Biomarker-only improvement without organismal benefit" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "no", "perturbation_result_note": "Short small studies did not test long-term net healthspan benefit or systematically ascertain serious harms.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Requires at least one endogenous perturbation showing the proposed feature contributes causally to the claimed output", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Khavinson et al. 2005 [14]; Al-Dulaimi et al. 2025 [3]", "gamma_hard_rules_triggered": [ "Sequence motif enrichment is Weak evidence", "In vitro evidence alone cannot exceed Γ" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "no", "perturbation_result_note": "The proximal gene-regulation step has no endogenous perturbation, no specificity control against global transcriptional effects, and no matched rescue.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.", "satisfied": "no", "supporting_evidence": [ "Direct telomerase assays are positive in cultured human cells [1,3]." ], "what_would_cross_it": "Demonstration of telomerase activation in a prospectively sampled human tissue after controlled Epitalon administration." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Biomarker change alone does NOT satisfy this threshold", "satisfied": "no", "supporting_evidence": [ "Cultured-cell telomere length increased in selected conditions [1,3]." ], "what_would_cross_it": "Randomized longitudinal human evidence of durable tissue-appropriate telomere preservation beyond measurement error and cell-composition change." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [ "Animal survival signals exist [4-8], but human interventions measure biomarkers or disease-specific outcomes [9-11]." ], "what_would_cross_it": "A controlled human intervention showing improvement in a prespecified validated healthspan or disability-free-survival endpoint." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Lifespan and/or healthspan extension with mechanistic specificity", "satisfied": "no", "supporting_evidence": [ "Cellular telomerase effects and organismal outcomes are reported in separate systems." ], "what_would_cross_it": "A matched perturbation, rescue, or human mediation analysis showing that blocking telomerase engagement abolishes the functional effect." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "At least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [ "Small short human studies establish exposure to the intervention but do not measure net long-term healthspan." ], "what_would_cross_it": "Long-term controlled human efficacy and safety follow-up showing a favorable net functional outcome." }, { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Critically: specificity against cell-cycle collapse, global transcriptional collapse, and replication stress must be demonstrated", "satisfied": "no", "supporting_evidence": [ "A complementarity model places the proposed binding block in the telomerase promoter region [14].", "Reported binding to methylated cytosine and linker histone is discussed as the basis for an alternative-lengthening effect in cancer cells [3]." ], "what_would_cross_it": "An endogenous perturbation of the proposed binding step with a matched rescue and demonstrated specificity against global transcriptional or cell-cycle disruption." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Normal-cell telomere and telomerase responses required three weeks of exposure in the 2025 study; four days produced no telomere increase in normal fibroblasts.", "Breast-cancer cell lines showed telomere elongation through an alternative-lengthening signal rather than increased telomerase activity, and the lowest concentration was followed by a telomere decrease in one of them.", "Telomerase activity in treated normal cells stayed below the level in untreated cancer lines.", "SHR mice showed no mean-lifespan change and a slightly lower median despite a longest-lived-tail signal.", "Rat survival signals appeared only in the naturally-lit and constantly-lit groups and were absent under a standard light cycle, in both sexes.", "The fly lifespan effect did not depend on dose across several orders of magnitude of exposure.", "Human interventions measured circadian or disease-specific outcomes and did not show the predicted telomerase-healthspan chain." ], "note": "The boundary between selected cell contexts, conditional animal signals, and absent human healthspan evidence is mapped, and several of the mapping observations are internal to the studies themselves. This does not establish context-specific human causality because no human healthspan perturbation is positive, and mapped boundaries in non-human systems cannot carry a human-scoped claim to Ε." }, "falsification_patterns_met": [ { "subclaim_id": "SC3", "pattern": "Pathway manipulation changes biomarkers but not lifespan/healthspan.", "evidence": "Human Epitalon interventions report melatonin and clock-gene changes without a validated healthspan endpoint [9,10].", "downgrade_applied": true }, { "subclaim_id": "SC3", "pattern": "Developmental effects are not separated from true aging effects.", "evidence": "The fly study exposed animals only from egg through larval development, and the reported lifespan increase did not depend on dose across several orders of magnitude [4].", "downgrade_applied": true }, { "subclaim_id": "SC3", "pattern": "An organismal intervention fails on a central lifespan summary despite a positive secondary survival signal.", "evidence": "Female SHR mice had no mean-lifespan difference and a lower median in the treated group, while the longest-lived tail and maximum lifespan were emphasised [6]; male rats showed virtually unchanged mean lifespan [8].", "downgrade_applied": true }, { "subclaim_id": "SC4", "pattern": "Necessity fails to be tested when the proposed pathway is removed.", "evidence": "No telomerase inhibition, matched rescue, inactive-analogue control or mediation experiment tests whether the reported organismal signals require telomerase, although the design for such a test exists in the telomerase gene-therapy literature [18].", "downgrade_applied": true }, { "subclaim_id": "SC3", "pattern": "Benefits are explained by an induced pathology rather than by ageing.", "evidence": "Rat survival signals appear in animals under natural or constant illumination and are absent under a standard light cycle, in both sexes [8,13].", "downgrade_applied": true } ], "pitfalls_flagged": [ { "subclaim_id": "SC1", "pitfall": "4. In vitro reconstitution treated as demonstration of endogenous function", "where": "Cultured-cell telomerase activation is kept separate from target engagement after administration to people." }, { "subclaim_id": "SC3", "pitfall": "8. Confirmation by biomarker", "where": "Melatonin, clock-gene, telomerase, and telomere measurements are not counted as human healthspan." }, { "subclaim_id": "SC3", "pitfall": "7. Selective generalization", "where": "Single-strain, developmental, sex-specific, and lighting-dependent animal results are not generalized to humans." }, { "subclaim_id": "SC4", "pitfall": "10. Mechanism conflation", "where": "Telomerase activation, telomere maintenance, healthspan benefit, and mediation are scored as distinct subclaims." }, { "subclaim_id": "SC4", "pitfall": "11. Intervention specificity assumed rather than demonstrated", "where": "Circadian and other peptide actions remain alternatives because telomerase necessity has not been tested." }, { "subclaim_id": "SC3", "pitfall": "9. Replication confused with reproduction", "where": "Multiple animal and human reports from a connected research program are not counted as independent causal lines." }, { "subclaim_id": "SC4", "pitfall": "14. Missing-control interpretation", "where": "No study of this peptide reports an inactive-analogue, blockade or rescue control, which the telomerase gene-therapy literature shows is the control that makes such a result mechanism-specific." }, { "subclaim_id": "SC5", "pitfall": "8. Confirmation by biomarker", "where": "Telomere length is itself treated as the good to be maximised; human genetic evidence shows its relation to disease runs in both directions." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 0, "items_rejected": [ "Cultured-cell telomerase and telomere effects do not count as a human healthspan perturbation.", "Developmental-only Drosophila exposure does not separate development from aging.", "Single-network rodent lifespan reports do not establish an independent human causal line.", "Human melatonin and clock-gene shifts are biomarkers, not validated healthspan endpoints.", "Retinitis-pigmentosa outcomes are disease-specific and do not test systemic aging.", "Epithalamin and Thymalin survival reports concern different preparations and cannot be counted for synthetic Epitalon.", "Germline telomere-length genetics is association evidence about a different exposure and cannot count as a causal perturbation of this intervention.", "Telomerase gene therapy in mice is a different intervention in a different species and is overexpression evidence, capped for endogenous-pathway claims.", "An independent bovine embryo-production study is cultured non-human material with a reproductive endpoint." ] }, "steelman": { "case_one_rung_higher": "A Δ case can be made because the peptide is a direct intervention, several animal studies report survival effects, two laboratories report telomerase-related effects in cultured human cells and a third in bovine cells, and, decisively for the mechanism class, telomerase activation by gene therapy in one- and two-year-old mice produced healthspan improvements and a median-lifespan increase with no excess cancer, an effect abolished by a catalytically inactive enzyme.", "case_one_rung_lower": "A Β case can be made because organismal findings are concentrated in one research network, the independent cell study required replacement of all three core data figures, the fly effect was dose-independent, the most auditable mouse result was null on mean and median, and no human telomerase-healthspan chain has been observed.", "which_rejected": "The higher case is rejected because the metabolism-and-aging Δ threshold requires a field-valid intervention changing the claimed lifespan or healthspan endpoint and requires developmental effects to be separated from ageing effects: no human healthspan study exists, the rodent record for this peptide is null on its central summaries, developmental in the fly and confined to circadian-disrupted groups in the rat, and the mouse gene-therapy result is a different intervention in another species, capped at Γ for endogenous-pathway claims by universal cap 3. The lower case is rejected because controlled exposure of cultured human cells with direct telomerase and telomere readouts and internal negative controls is causal partial-system support rather than association alone.", "blocking_cap_threshold_or_missing_experiment": "The binding barrier is the Γ in-vitro and biomarker ceiling, reinforced by the epigenetics rubric's ceiling on the proximal step, and the missing controlled human trial linking in-vivo telomerase target engagement to a validated healthspan endpoint; the missing mechanistic experiment is a blockade-and-rescue or inactive-analogue test." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Confidence measures evidence density and reproducibility, not the reviewer's certainty about the verdict. Every criterion of the framework's Low band is met on evidence grounds alone: the literature is small; eleven of the twelve sources in the prior edition originate in one connected research network and its declared collaborators, the sole exception being the 2025 independent cell-line study; no organism-level result has been reproduced outside that network; and the single independent human-cell study required replacement of all three core data figures. The band does not rest on how much of any paper could be read: that two rodent survival reports are available only as English abstracts and two primaries are image-only scans is recorded as an access limitation in REVIEWER NOTES and is not a confidence determinant. The prior edition assigned High on the ground that confidence in the location of the ceiling was high, which is the reading the framework explicitly rules out. The level itself is stable, and that is a separate axis.", "rests_on_non_peer_reviewed_work": false, "rationale": "Cultured-cell findings in three laboratories make telomerase activation mechanistically plausible. The claim cannot cross Δ because no intervention with this peptide demonstrates telomerase activation in living humans, durable human telomere maintenance, or extension of validated human healthspan, and no study in any system establishes telomerase mediation. At the claimed human scope there is no evidence at all; the level is carried by cell-culture and animal systems, which is what Γ describes." }, "role_of_mechanism": { "classification": "epiphenomenon", "derivation_step_matched": "2", "derivation": "Step 1 does not match: nothing addresses whether the mechanism is produced by the phenotype. Step 2 matches and the derivation stops there: at the scope this classification attaches to, human ageing trajectories and healthspan, no causal dependency has been demonstrated in either direction. No human study measures the mechanism, no necessity or rescue test exists in any system, and no mediation analysis links the mechanism to a functional outcome. The prior edition recorded reinforcing / stabilizing factor, which is step 5 and requires evidence that the mechanism amplifies or maintains the phenotype; its own derivation conceded that role was unproven and labelled it provisional, and missing evidence does not earn benefit of the doubt.", "tournament_used_as_tiebreaker": false, "note": "This classification does not assert that the peptide is biologically inert. A bounded causal dependency is demonstrated in cell culture, where exposure was followed by raised telomerase expression and activity, longer telomeres and additional population doublings; that is recorded at its own scope under SC1. Role classification never modifies the HSEF level." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Causal output since the prior scored literature is mechanistic and in vitro: the corrected 2025 independent cell-line study, an independent bovine embryo-production study, an independent study in injured human retinal pigment epithelium that measures no telomerase, same-network work on senescence markers, and two reviews. ClinicalTrials.gov searches on 2026-09-30 for the peptide's names, and separately for the two extract preparations, returned no registered study.", "justification": "Recent work addresses cellular mechanism and adjacent disease models but nothing addresses the boundary check, and the 2026 regulatory record advanced with no new clinical data." }, "stability": { "value": "Stable", "trigger": "No registered or otherwise identifiable pending human study measures both telomerase target engagement and a healthspan endpoint; registry searches were re-run on 2026-09-30. A registered trial of that design would make the assessment Rising.", "justification": "No named near-term result can be identified that would move the level; by the framework definition the assessment is Stable." }, "divergence": { "implied_level": "Ζ", "implied_level_basis": "Computed from the literature's own artifacts rather than its tone: the titles 'Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells', 'Peptide promotes overcoming of the division limit in human somatic cell' with its conclusion that the peptide prolonged the vital cycle of normal human cells by overcoming the Hayflick limit, 'Peptides of pineal gland and thymus prolong human life', and 'Geroprotective effect of Ala-Glu-Asp-Gly peptide'; and the independent 2025 paper's conclusion that the peptide can be safely used in healthy individuals to maintain telomeres and thereby influence the aging process. A competent reader would infer replicated organism-level causal benefit with safety established.", "assessed_level": "Γ", "gap_in_rungs": 3, "value": "Severe overstatement", "justification": "The field-facing framing of this peptide implies Ζ while the assessed level is Γ; Γ to Ζ is a three-rung positive gap. This applies to this peptide's own literature and its commercial-style downstream framing, not to geroscience as a whole." }, "calibration_note": "M/S/D never modify HSEF level or confidence (Rule 10). Each is tied to a checkable artifact." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": "none assigned", "prior_source": "No prior scored review was found; the website register contained only an ungraded coming-soon entry.", "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "raised", "what_moved_it": "The in-vitro, biomarker and rubric ceilings bind, and no human healthspan intervention crosses the Δ threshold. In the cross-model red-team pass the level was argued in both directions and held; the confidence band moved from High to Low and the role of mechanism from reinforcing / stabilizing factor to epiphenomenon.", "divergence_from_other_reviewers": "No prior scored HSEF review was available for comparison. The red-team pass by a different model family agreed with the authoring run on the level and on all five subclaim levels, and disagreed on the confidence band, the role classification, four factual statements, and the completeness of the rubric routing and the evidence base." }, "proposed_decisive_experiments": [ { "name": "Human target-engagement and healthspan trial", "experiment": "A preregistered, double-blind randomized trial of synthetic Epitalon of documented identity and purity in an older population, with baseline stratification fixed before outcomes and follow-up long enough to measure functional ageing and to be informative about cancer incidence.", "readout": "Direct telomerase activity in prospectively sampled tissues, tissue-appropriate telomere dynamics, a validated multidomain healthspan or disability-free-survival endpoint, morbidity, and systematic adverse outcomes.", "critical_control": "Placebo, blinded allocation and analysis, batch identity and pharmacokinetics, cell-composition adjustment, prespecified multiplicity control, and a plan separating transient biomarker change from durable functional benefit.", "falsifying_result": "Adequate exposure without in-vivo telomerase engagement, or target engagement without durable functional benefit.", "supporting_result": "Replicated target engagement and telomere preservation accompanied by a prespecified clinically meaningful healthspan improvement and acceptable long-term net outcomes." }, { "name": "Telomerase-mediation test", "experiment": "Use matched human primary-cell and tissue systems in which Epitalon exposure is combined with selective TERT or telomerase-pathway inhibition and a pathway-specific rescue.", "readout": "Telomerase activity, shortest-telomere burden, replicative function, senescence-independent cell fitness, and off-target transcriptomic responses.", "critical_control": "Matched vehicle, telomerase inhibition alone, a rescue that restores telomerase without reproducing unrelated peptide effects, a sequence-scrambled or otherwise inactive peptide control by analogy with the catalytically inactive enzyme arm that made the mouse gene-therapy result mechanism-specific, and blinded assay replication in an independent laboratory. The proximal chromatin step should be tested in the same design with specificity against global transcriptional disruption.", "falsifying_result": "Epitalon-related cellular effects persist when telomerase is selectively blocked or cannot be restored by pathway-specific rescue.", "supporting_result": "Selective blockade abolishes the telomere and functional effects, while pathway-specific rescue restores them." }, { "name": "Independent late-life preclinical aging study", "experiment": "Independent laboratories administer synthetic Epitalon of documented identity beginning late in life in at least two mammalian backgrounds, both sexes, under a standard light cycle and with a circadian-disrupted arm, since the existing rat signal appears only under disrupted lighting.", "readout": "Survival, frailty, physical and cognitive function, morbidity, food intake, body weight, tumor incidence, pharmacokinetics, tissue telomerase activity, and telomere dynamics.", "critical_control": "Late-life start, pair-feeding or intake adjustment given the higher food consumption observed in treated mice, blinded allocation and outcome scoring, a prospectively specified primary endpoint, and full-cohort survival analysis reporting mean and median rather than the longest-lived tail.", "falsifying_result": "No reproducible lifespan or healthspan benefit despite adequate exposure, or apparent benefit explained by sickness, intake, development, or one background.", "supporting_result": "Concordant late-life healthspan benefit across independent laboratories and backgrounds with target engagement and no major trade-off." } ], "knowledge_gaps": [ { "name": "Human target engagement", "statement": "It is unknown whether administered synthetic Epitalon reaches relevant human tissues and activates telomerase at tolerable exposure.", "relevance": "Without this, cell-culture activity cannot be connected to the human claim." }, { "name": "Human telomere consequence", "statement": "No longitudinal human study establishes durable tissue-specific telomere preservation attributable to Epitalon rather than measurement error or cell-composition change.", "relevance": "This is the proposed intermediate between telomerase activation and healthspan." }, { "name": "Validated human healthspan outcome", "statement": "No synthetic-Epitalon study measures validated multidomain function, morbidity, or disability-free survival.", "relevance": "This missing endpoint is the direct barrier to Δ for the main claim." }, { "name": "Mechanistic mediation", "statement": "No study tests whether reported cellular, circadian, or organismal effects require telomerase, and no inactive-analogue, blockade or rescue control has been reported for this peptide in any system.", "relevance": "Without necessity or mediation, non-telomerase explanations remain viable." }, { "name": "Product identity and pharmacology", "statement": "Epitalon is often discussed alongside Epithalamin, but the latter is a heterogeneous pineal preparation; no cited study reports verification of the identity or purity of the material it used; and human pharmacokinetics for the defined tetrapeptide are absent from the identified literature and from the regulatory record.", "relevance": "Chemical identity and exposure determine whether adjacent clinical reports can inform the hypothesis." }, { "name": "Long-term safety", "statement": "Systematic human safety follow-up over a healthspan-relevant horizon is absent.", "relevance": "Net healthspan benefit cannot be inferred from short biomarker studies, and telomerase-related trade-offs require empirical rather than theoretical resolution." }, { "name": "The proximal step", "statement": "How a tetrapeptide reaches and acts on the telomerase gene rests on a sequence-complementarity model and reported DNA and histone binding; independent structural and binding work is absent, and under the epigenetics rubric this is the weakest-tier evidence in the chain.", "relevance": "It is the least-studied link in a chain whose distal end is the claim being advertised." }, { "name": "Whether telomere lengthening is a net good in humans", "statement": "Human genetic evidence links longer telomeres to higher risk of several cancers and lower risk of some non-neoplastic diseases, and concerns lifelong germline variation rather than adult pharmacological lengthening.", "relevance": "The hypothesis's final step, from telomere maintenance to net healthspan gain, is a substantive empirical question rather than a corollary." } ], "review_metadata": { "review_date": "2026-09-30", "reviewer": "Authored by OpenAI Codex using HSEF v5.4 (2026-09-27); red-teamed and rewritten by Claude (Anthropic) as the cross-model red team and synthesizer (2026-09-30)", "evidence_base_note": "Primary literature and accessible regulatory and registry context through 2026-09-30. Every identifier was resolved with PubMed tools in the red-team pass; ClinicalTrials.gov was re-searched; the FDA evaluation was re-read. Full text was read where machine-readable. Two primaries are image-only scans and are treated at abstract-and-metadata depth, with the specifics that only those scans supported withdrawn.", "literature_tools_available": true, "literature_tools_note": "PubMed and PubMed Central via MCP tools, ClinicalTrials.gov via MCP tools, publisher and repository PDFs, and the FDA document were used. Scite was unavailable, so citation-context counts are omitted rather than recorded as zero.", "skill_version": "5.4", "validator_run": "pass", "validator_warnings_addressed": "Validator 2.4 returned 34 pass, 0 warn, 0 fail on the prior edition, and validator 2.2 from the supplied packet returned 27 pass, 0 warn, 0 fail on it. A structural validator cannot detect a reversed direction of effect, a boundary condition absent from the cited paper, a confidence band derived from the wrong definition, or a role classification that skips a step; all four were present and are corrected. The final pair was re-validated with 2.2.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": false, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "No sealed calibration target was supplied.", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Standalone evaluation; no independently authored sealed expected band was supplied." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "No valid genetic instrument exists for exposure to the synthetic peptide. Instruments do exist for the proposed mediator, telomere length, and the large Mendelian-randomization and polygenic analyses are reported in the review; they cannot carry this claim because the exposure is lifelong germline variation rather than administration of a compound, because they are association-based and capped by universal cap 2, and because their direction of effect differs by outcome." }, { "kind": "multiple_pharmacological_classes", "available": false, "why_not_sufficient": "No independent drug class reproduces a peptide-specific telomerase-mediated human healthspan effect. Telomerase gene therapy in old mice acts on the same node with a concordant organismal endpoint, but it is a different modality in a different species and is overexpression evidence, so it does not establish convergence for this claim." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "No natural experiment creates differential lifelong exposure to the synthetic peptide." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "There is no comparable human population dose-response linking Epitalon exposure to validated healthspan." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Human interventions report biomarkers or disease-specific outcomes rather than a hard aging or healthspan endpoint." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 22, "claims_total": 21, "claims_verified": 21, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 20, "tier_b_sources": 2, "generated_by": "Authored by OpenAI Codex with HSEF v5.4; red-team synthesis by Claude (Anthropic); validator 2.2 from the supplied packet", "gate_passed": true }, "claims": [ { "id": "C1", "text": "In telomerase-negative human fetal lung fibroblast culture, exposure to the peptide was followed by induction of the telomerase catalytic subunit, telomerase enzymatic activity and telomere elongation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "The arbitrary-unit telomere values and the HeLa positive control reported in the prior edition are withdrawn: the primary is an image-only scan and they could not be re-verified." }, { "id": "C2", "text": "A follow-up from the same research program reported that untreated fetal fibroblasts stopped dividing at passage 34, whereas Epitalon-exposed cells reached passage 44 and retained telomere length comparable to earlier-passage cells.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Not counted as an independent laboratory line." }, { "id": "C3", "text": "In the independent 2025 study, normal human fibroblast and mammary epithelial lines treated daily for three weeks showed longer telomeres, increased hTERT mRNA, and telomerase activity approximately fourfold and twenty-sixfold above untreated controls respectively, while remaining below the telomerase activity of untreated cancer lines.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Corrected PMC full text, results and discussion", "verified_on": "2026-09-30", "note": "All three core figures were replaced by a published erratum from the same authors; the corrected version was read and its values are used." }, { "id": "C4", "text": "In the same study, normal fibroblasts treated for four days showed no telomere increase; breast-cancer lines treated for four days showed telomere elongation and raised hTERT mRNA without a significant rise in telomerase activity, with roughly tenfold and threefold increases in C-circle alternative-lengthening activity confirmed by elevated PML bodies, and no such activation in the normal lines.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Corrected PMC full text, figures and discussion", "verified_on": "2026-09-30", "note": "Internal context boundary, and the corpus's most directly safety-relevant in-vitro observation." }, { "id": "C5", "text": "A fly study reported an 11-16% increase in adult mean lifespan after exposure confined to the egg-to-larval developmental period, with effective concentrations spanning several orders of magnitude and an increase that the paper states did not depend on dose.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Developmental exposure prevents an ageing-specific interpretation, and dose-independence across orders of magnitude argues against a saturable pharmacological mechanism." }, { "id": "C6", "text": "In female outbred SHR mice, mean lifespan was 455 plus or minus 31 days with the peptide against 456 plus or minus 29 in controls and the median was lower in the treated group, 487 against 512 days, while the mean lifespan of the last ten per cent was 803 plus or minus 15.0 against 709 plus or minus 10.8 days, a 13.3% increase, and maximum lifespan was 830 against 739 days, a 12.3% increase.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary PDF, survival table, and PubMed abstract", "verified_on": "2026-09-30", "note": "Both central summaries were null or slightly unfavourable. The prior edition reported the median as favouring treatment; corrected here." }, { "id": "C7", "text": "A female CBA mouse report describes prolonged lifespan, slowed loss of estrous function and reduced tumour incidence after treatment from six months of age, and a senescence-accelerated mouse report describes longer mean and maximum survival among the last ten per cent with no effect on tumour frequency; the accessible English abstracts do not establish independently replicated whole-cohort healthspan effects or telomerase mediation.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 5, 7 ], "verification": "verified", "verified_against": "PubMed English abstracts and metadata", "verified_on": "2026-09-30", "note": "No inaccessible full-text detail was imported." }, { "id": "C8", "text": "In rats under standard, natural and constant illumination, mean lifespan was virtually unchanged and the peptide normalised population ageing rate and mortality-rate doubling time in the naturally-lit and constantly-lit groups while inhibiting spontaneous tumours under every regimen; in the female companion study maximum lifespan was prolonged by 95 and 24 days under natural and constant light and lifespan was unchanged under the standard regimen.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 8, 13 ], "verification": "verified", "verified_against": "PubMed records and abstracts of both rat studies", "verified_on": "2026-09-30", "note": "The prior edition attributed the maximum-lifespan effect to constant darkness; neither study has a constant-darkness arm." }, { "id": "C9", "text": "A report on pineal peptide preparations describes restored night melatonin release in elderly people with pineal functional insufficiency; it covers the heterogeneous pineal extract and the synthetic tetrapeptide together, states no allocation, duration or sample size, and measures neither telomerase nor telomeres nor healthspan.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4", "SC5" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "PubMed record and abstract, cross-checked against the 2026 regulatory evaluation's account", "verified_on": "2026-09-30", "note": "Biomarker report, not a healthspan trial. The prior edition's randomisation, placebo and ten-day-course specifics are withdrawn as unsupported by any accessible source." }, { "id": "C10", "text": "A study of seventy-five women aged forty to fifty working mainly night shifts, with thirty-five as an age-appropriate comparison group and forty with low melatonin-metabolite excretion allocated twenty per arm for twenty days, reported increased urinary 6-sulfatoxymelatonin excretion and normalised clock-gene expression; blinding was not specified, and no validated functional outcome or systematic safety data were reported.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4", "SC5" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "PubMed record and abstract for the reported gene and metabolite changes; design details from the 2026 regulatory evaluation's synthesis of the primary Russian text", "verified_on": "2026-09-30", "note": "A second paper from the same cohort is not counted as an independent study. The subjective condition ratings reported in the synthesis are not treated as a functional outcome because no instrument is described." }, { "id": "C11", "text": "A retinitis-pigmentosa report combining an animal component with a clinical component in which the peptide was administered locally to the eye describes a positive clinical effect in 90% of cases, with unclear allocation and blinding and no measurement of systemic ageing, telomerase, telomeres or healthspan.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4", "SC5" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Disease-specific evidence only." }, { "id": "C12", "text": "The long-term human mortality report commonly cited in this area administered Epithalamin and Thymalin to 266 elderly people over six to eight years, not the chemically defined synthetic tetrapeptide.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Product-identity boundary." }, { "id": "C13", "text": "Across the identified human studies of the synthetic peptide, none measured telomerase enzyme activity or telomere length after administration, and none used a validated human healthspan endpoint.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 9, 10, 11, 21 ], "verification": "verified", "verified_against": "Primary records for all identified human reports, cross-checked against PubMed name searches, the 2026 regulatory evaluation's statement that telomere and telomerase measurements were made only in cell culture, and ClinicalTrials.gov exact-name searches on 2026-09-30", "verified_on": "2026-09-30", "note": "Bounded to the searched literature through the review date. One same-network review reports regulation of telomere-associated marker proteins in buccal epithelium; whether administration to people is involved cannot be determined from its accessible abstract, and this is recorded as an open issue." }, { "id": "C14", "text": "The identified human reports provide no pharmacokinetic characterisation and no systematic long-term safety ascertainment sufficient to evaluate net healthspan benefit, and the 2026 regulatory record states that no pharmacokinetic data and no clinical safety data were found.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 9, 10, 11, 22 ], "verification": "verified", "verified_against": "Human primary abstracts, the full 2026 FDA evaluation, and a peer-reviewed analysis of the compounding advisory committee's recommendations", "verified_on": "2026-09-30", "note": "The FDA evaluation is used for cross-checking and is not counted as a ledger source because it carries no identifier; the peer-reviewed analysis is." }, { "id": "C15", "text": "In the same SHR mouse study, total spontaneous tumour incidence was 32% with the peptide against 36% in controls, leukaemia occurred in 1 treated animal against 6 controls, bone-marrow chromosome aberrations at 12 months were 6.8 plus or minus 0.21% against 8.2 plus or minus 0.41%, and treated mice consumed more food from the fifth to the sixteenth month with no body-weight difference at any period.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary PDF, food-consumption table, tumour table and chromosome-aberration results", "verified_on": "2026-09-30", "note": "Restored because the prior edition reported the study's null and unfavourable results without its favourable ones; the higher food intake is a listed confounder in this field and its direction matters." }, { "id": "C16", "text": "Human genetic studies of the proposed mediator report that genetically higher telomere length is associated with higher odds of several site-specific cancers and lower odds of some non-neoplastic diseases, and that shorter leukocyte telomere length at age forty is associated with lower life expectancy than longer length.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 19, 20 ], "verification": "verified", "verified_against": "PubMed records and abstracts, with odds ratios and confidence intervals taken verbatim into the prose", "verified_on": "2026-09-30", "note": "Concerns lifelong germline variation rather than adult pharmacological lengthening, and is association-based, so universal cap 2 bars it from raising any subclaim." }, { "id": "C17", "text": "Vector-delivered mouse TERT given to one- and two-year-old mice improved several healthspan measures and increased median lifespan by 24% and 13% respectively without increasing cancer relative to control littermates, and a catalytically inactive enzyme produced none of the benefits.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "The mechanism class's organism-level benchmark and the template for the specificity control this literature lacks; a different intervention and species, capped for endogenous-pathway claims." }, { "id": "C18", "text": "An independent laboratory reports that peptide-associated telomerase activation improved bovine oocyte maturation rate and post-thaw blastocyst hatching and implantation potential.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "A third laboratory outside the originating network, in cultured non-human material with a reproductive endpoint." }, { "id": "C19", "text": "An independent 2025 study reports that AEDG restored delayed wound healing in high-glucose-injured human retinal pigment epithelial cells by inhibiting epithelial-mesenchymal transition and fibrosis, attributed to antioxidant action, with no telomerase or telomere measurement.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Supports the non-telomerase competing model and is the closest mechanistic context for the retinal clinical report." }, { "id": "C20", "text": "The proposed proximal mechanism originates in a sequence-complementarity model that identifies a base-pair block as the peptide's binding site and reports that the block and its reverse complement occur repeatedly in the telomerase promoter region.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Motif occurrence is the weakest evidence tier of the epigenetics rubric; this claim carries the secondary rubric routing." }, { "id": "C21", "text": "An independent overview of the peptide records that its reported effects are attributed to several partly non-specific mechanisms and that its physico-chemical and structural characterisation remains limited.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "PubMed record and abstract", "verified_on": "2026-09-30", "note": "Tier B source, cited for framing and for the characterisation gap only." } ], "citation_ledger": [ { "n": 1, "citation": "Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592.", "tier": "A", "kind": "primary", "pmid": "12937682", "doi": "10.1023/A:1025493705728", "url": "https://pubmed.ncbi.nlm.nih.gov/12937682/", "status_flags": [ "none_found" ], "carries_claims": [ "C1" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-fetal-fibroblast-2003", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read in the red-team pass. The cited primary PDF is an image-only scan and yielded no machine-readable text, so the arbitrary-unit values reported in the prior edition were withdrawn." }, { "n": 2, "citation": "Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506.", "tier": "A", "kind": "primary", "pmid": "15455129", "doi": "10.1023/B:BEBM.0000038164.49947.8C", "url": "https://pubmed.ncbi.nlm.nih.gov/15455129/", "status_flags": [ "none_found" ], "carries_claims": [ "C2" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-fetal-fibroblast-2004", "access_depth": "abstract_metadata", "access_note": "Publisher abstract and metadata read." }, { "n": 3, "citation": "Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178.", "tier": "A", "kind": "primary", "pmid": "40908429", "doi": "10.1007/s10522-025-10315-x", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/", "status_flags": [ "published erratum: the wrong figures appeared as Figs. 1, 2 and 3; corrected versions supplied by the same authors; PMID 41240216; DOI 10.1007/s10522-025-10326-8; not a retraction and not an expression of concern" ], "carries_claims": [ "C3", "C4" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "al-dulaimi-cell-lines-2025", "access_depth": "full_text_complete", "access_note": "Complete PMC article and complete correction notice read; corrected figures used." }, { "n": 4, "citation": "Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000;120(1-3):141-149.", "tier": "A", "kind": "primary", "pmid": "11087911", "doi": "10.1016/S0047-6374(00)00217-7", "url": "https://pubmed.ncbi.nlm.nih.gov/11087911/", "status_flags": [ "none_found" ], "carries_claims": [ "C5" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-drosophila-2000", "access_depth": "full_text_partial", "access_note": "Abstract, methods, and accessible results excerpts read; full publisher text was not completely accessible." }, { "n": 5, "citation": "Anisimov VN et al. Effect of pineal peptide on parameters of the biological age and life span in mice. Ross Fiziol Zh Im I M Sechenova. 2001;87(1):125-136.", "tier": "A", "kind": "primary", "pmid": "11227856", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11227856/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "anisimov-cba-mice-2001", "access_depth": "abstract_metadata", "access_note": "PubMed English abstract and metadata read; Russian full text was not available through checked routes." }, { "n": 6, "citation": "Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202.", "tier": "A", "kind": "primary", "pmid": "14501183", "doi": "10.1023/A:1025114230714", "url": "https://pubmed.ncbi.nlm.nih.gov/14501183/", "status_flags": [ "none_found" ], "carries_claims": [ "C6", "C15" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "anisimov-shr-mice-2003", "access_depth": "full_text_complete", "access_note": "Complete primary PDF re-read: methods, survival table, food-consumption table, tumour table, chromosome-aberration results and discussion." }, { "n": 7, "citation": "Anisimov VN et al. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). Vopr Onkol. 2005;51(1):93-98.", "tier": "A", "kind": "primary", "pmid": "15909815", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15909815/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "anisimov-sam-mice-2005", "access_depth": "abstract_metadata", "access_note": "PubMed English abstract and metadata read; Russian full text was not available through checked routes." }, { "n": 8, "citation": "Vinogradova IA et al. Geroprotective effect of Ala-Glu-Asp-Gly peptide in male rats exposed to different illumination regimens. Bull Exp Biol Med. 2008;145(4):472-477.", "tier": "A", "kind": "primary", "pmid": "19110597", "doi": "10.1007/s10517-008-0121-7", "url": "https://pubmed.ncbi.nlm.nih.gov/19110597/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "vinogradova-male-rats-2008", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read in the red-team pass; the cited primary PDF is an image-only scan. The companion female-rat study was added to supply the maximum-lifespan figures." }, { "n": 9, "citation": "Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007;20(1):74-85.", "tier": "A", "kind": "primary", "pmid": "17969590", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17969590/", "status_flags": [ "none_found" ], "carries_claims": [ "C9", "C13", "C14" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "korkushko-melatonin-humans-2007", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; the primary is an image-only scan. Allocation, blinding, duration and sample size are not available in any accessible source, as the 2026 regulatory evaluation also records. The report covers two different preparations together." }, { "n": 10, "citation": "Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol. 2020;33(3):429-435.", "tier": "A", "kind": "primary", "pmid": "33280326", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33280326/", "status_flags": [ "none_found" ], "carries_claims": [ "C10", "C13", "C14" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "ivko-night-shift-aedg-2020", "access_depth": "full_text_partial", "access_note": "PubMed record and abstract read; design details taken from the 2026 regulatory evaluation's synthesis of the primary Russian text and attributed to it in the prose. Blinding was not specified. A second paper from the same cohort is treated as the same study." }, { "n": 11, "citation": "Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368.", "tier": "A", "kind": "primary", "pmid": "12195242", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12195242/", "status_flags": [ "none_found" ], "carries_claims": [ "C11", "C13", "C14" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-retinitis-2002", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; the cited primary PDF is an image-only scan. PubMed types the report as a controlled clinical trial; allocation and blinding are not described in the accessible record." }, { "n": 12, "citation": "Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240.", "tier": "A", "kind": "primary", "pmid": "14523363", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/14523363/", "status_flags": [ "none_found" ], "carries_claims": [ "C12" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-epithalamin-thymalin-2003", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; used only to police product identity." }, { "n": 13, "citation": "Vinogradova IA, Bukalev AV, Zabezhinski MA, Semenchenko AV, Khavinson VKh, Anisimov VN. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bull Exp Biol Med. 2007;144(6):825-830.", "tier": "A", "kind": "primary", "pmid": "18856211", "doi": "10.1007/s10517-007-0441-z", "url": "https://pubmed.ncbi.nlm.nih.gov/18856211/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "vinogradova-female-rats-2007", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read." }, { "n": 14, "citation": "Khavinson V, Shataeva L, Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237-241.", "tier": "A", "kind": "primary", "pmid": "15990728", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15990728/", "status_flags": [ "none_found" ], "carries_claims": [ "C20" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "khavinson-dna-binding-2005", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read." }, { "n": 15, "citation": "Ullah S, Haider Z, Perera CD, Lee SH, Idrees M, Park S, Kong IK. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sci. 2025;362:123381.", "tier": "A", "kind": "primary", "pmid": "39788414", "doi": "10.1016/j.lfs.2025.123381", "url": "https://pubmed.ncbi.nlm.nih.gov/39788414/", "status_flags": [ "none_found" ], "carries_claims": [ "C18" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "ullah-bovine-oocytes-2025", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read." }, { "n": 16, "citation": "Gatta M, Dovizio M, Milillo C, et al. The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Rev Rep. 2025;21(6):1822-1834.", "tier": "A", "kind": "primary", "pmid": "40493162", "doi": "10.1007/s12015-025-10911-x", "url": "https://pubmed.ncbi.nlm.nih.gov/40493162/", "status_flags": [ "none_found" ], "carries_claims": [ "C19" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "gatta-arpe19-2025", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read." }, { "n": 17, "citation": "Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon - highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691.", "tier": "B", "kind": "review", "pmid": "40141333", "doi": "10.3390/ijms26062691", "url": "https://pubmed.ncbi.nlm.nih.gov/40141333/", "status_flags": [ "none_found" ], "carries_claims": [ "C21" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "araj-overview-2025", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; framing only, no number taken." }, { "n": 18, "citation": "Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med. 2012;4(8):691-704.", "tier": "A", "kind": "primary", "pmid": "22585399", "doi": "10.1002/emmm.201200245", "url": "https://pubmed.ncbi.nlm.nih.gov/22585399/", "status_flags": [ "none_found" ], "carries_claims": [ "C17" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "bernardes-tert-gene-therapy-2012", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; all quoted figures are stated in the abstract." }, { "n": 19, "citation": "Haycock PC, Burgess S, Nounu A, et al; Telomeres Mendelian Randomization Collaboration. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol. 2017;3(5):636-651.", "tier": "A", "kind": "primary", "pmid": "28241208", "doi": "10.1001/jamaoncol.2016.5945", "url": "https://pubmed.ncbi.nlm.nih.gov/28241208/", "status_flags": [ "none_found" ], "carries_claims": [ "C16" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "haycock-telomere-mr-2017", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; odds ratios and confidence intervals taken verbatim." }, { "n": 20, "citation": "Codd V, Wang Q, Allara E, et al. Polygenic basis and biomedical consequences of telomere length variation. Nat Genet. 2021;53(10):1425-1433.", "tier": "A", "kind": "primary", "pmid": "34611362", "doi": "10.1038/s41588-021-00944-6", "url": "https://pubmed.ncbi.nlm.nih.gov/34611362/", "status_flags": [ "none_found" ], "carries_claims": [ "C16" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "codd-ltl-polygenic-2021", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read." }, { "n": 21, "citation": "Ivko OM, Trofimova SV, Trofimov AV, Sharkovich Z, Mogilev VA. Peptidergic regulation of expression of cellular aging marker proteins in buccal epithelium. Adv Gerontol. 2024;37(5):516-524.", "tier": "A", "kind": "review", "pmid": "39742404", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39742404/", "status_flags": [ "none_found" ], "carries_claims": [ "C13" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "ivko-buccal-epithelium-2024", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; Russian-language review, cited to bound the absence claim and flagged as an open issue." }, { "n": 22, "citation": "Willis J, Vu N. Synthetic peptides in pharmacy compounding: analysis of PCAC recommendations and industry safety standards. Int J Pharm Compd. 2026;30(4):329-336.", "tier": "B", "kind": "review", "pmid": "42752426", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42752426/", "status_flags": [ "none_found" ], "carries_claims": [ "C14" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "willis-vu-compounding-2026", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; regulatory context with an identifier." } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": false, "note": "No level of Ζ or above is assigned. Three laboratories now report bounded cellular effects, which raises confidence in a cell-culture response and is why SC1 is held at Moderate, but replication does not add a causal line and none of the three is an organism-level line for human healthspan. No organism-level result has been reproduced outside the originating research network." }, "redteam_synthesis": { "date": "2026-09-30", "red_team_model": "Claude (Anthropic), cross-model red team; authoring model(s) differed", "inputs": [ "epitalon-telomerase-human-healthspan-hsef-v54-review.md", "epitalon-telomerase-human-healthspan-hsef-v54-scorecard.json (schema 5.4)", "epitalon-telomerase-human-healthspan-hsef-v54-validation.txt (validator 2.4)", "README-epitalon-telomerase-hsef-v54.txt" ], "mode": "single-version red team", "findings_total": 27, "findings_accepted": 24, "findings_rejected": 3, "findings_accepted_note": "24 accepted includes 2 partially accepted (RT-03, RT-21).", "findings_by_severity": { "Critical": 2, "Major": 13, "Minor": 10, "Editorial": 2 }, "score_before": { "level": "Γ", "confidence": "High", "role_of_mechanism": "reinforcing / stabilizing factor" }, "score_after": { "level": "Γ", "confidence": "Low", "role_of_mechanism": "epiphenomenon" }, "grade_changed": false, "grade_change_rationale": "The level held at Γ after arguments in both directions were rejected on rubric text: Β because the corpus contains controlled perturbation of human cells with direct molecular readouts and organism-level dosing with survival endpoints in three species, not correlation; and Δ because no intervention changes a claimed lifespan or healthspan endpoint at the claimed scope, with universal caps 1 and 4 and both rubrics' Γ caps binding. Two score elements did change. Confidence moved High to Low because the framework defines confidence as evidence density and reproducibility and every criterion of its Low band is met, the prior rationale having applied a reading the framework rules out. Role of mechanism moved from reinforcing / stabilizing factor to epiphenomenon because the five-step derivation matches at step 2 and the prior classification was recorded at step 5 without the evidence step 5 requires. Subclaim confidences for SC2 to SC5 moved High to Low; SC1 held at Moderate.", "citations_checked": 24, "citations_corrected": 0, "citations_removed": 0, "citations_added": 10, "citation_note": "All 12 identifiers in the prior edition resolved to exactly the paper cited, with title, first author, year, journal and pagination matching; the erratum on source 3 is real and was correctly attached to its parent row rather than given a row of its own. No confabulated identifier was found and no source was removed. Claims attached to four sources were rewritten or withdrawn: the arbitrary-unit values on source 1, the median direction on source 6, the lighting attribution on source 8, and the design specifics on source 9. Ten verified references were added, and the unnumbered regulatory artifact was fetched and confirmed.", "rubric_routing_changed": true, "rubric_routing_note": "03-epigenetics-gene-regulation.md added as a secondary rubric governing the proposed proximal gene-regulation step. Both rubrics return a Γ ceiling, so the cross-field lowest-ceiling rule leaves the level unchanged.", "audit_trail": "redteam/REDTEAM_REPORT.md; redteam/SYNTHESIS_CHANGE_LOG.md" }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Confidence measures evidence density and reproducibility, not the reviewer's certainty about the verdict. Every criterion of the framework's Low band is met on evidence grounds alone: the literature is small; eleven of the twelve sources in the prior edition originate in one connected research network and its declared collaborators, the sole exception being the 2025 independent cell-line study; no organism-level result has been reproduced outside that network; and the single independent human-cell study required replacement of all three core data figures. The band does not rest on how much of any paper could be read: that two rodent survival reports are available only as English abstracts and two primaries are image-only scans is recorded as an access limitation in REVIEWER NOTES and is not a confidence determinant. The prior edition assigned High on the ground that confidence in the location of the ceiling was high, which is the reading the framework explicitly rules out. The level itself is stable, and that is a separate axis.", "rests_on_non_peer_reviewed_work": false, "rationale": "Cultured-cell findings in three laboratories make telomerase activation mechanistically plausible. The claim cannot cross Δ because no intervention with this peptide demonstrates telomerase activation in living humans, durable human telomere maintenance, or extension of validated human healthspan, and no study in any system establishes telomerase mediation. At the claimed human scope there is no evidence at all; the level is carried by cell-culture and animal systems, which is what Γ describes." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Confidence measures evidence density and reproducibility, not the reviewer's certainty about the verdict. Every criterion of the framework's Low band is met on evidence grounds alone: the literature is small; eleven of the twelve sources in the prior edition originate in one connected research network and its declared collaborators, the sole exception being the 2025 independent cell-line study; no organism-level result has been reproduced outside that network; and the single independent human-cell study required replacement of all three core data figures. The band does not rest on how much of any paper could be read: that two rodent survival reports are available only as English abstracts and two primaries are image-only scans is recorded as an access limitation in REVIEWER NOTES and is not a confidence determinant. The prior edition assigned High on the ground that confidence in the location of the ceiling was high, which is the reading the framework explicitly rules out. The level itself is stable, and that is a separate axis.", "rests_on_non_peer_reviewed_work": false, "rationale": "Cultured-cell findings in three laboratories make telomerase activation mechanistically plausible. The claim cannot cross Δ because no intervention with this peptide demonstrates telomerase activation in living humans, durable human telomere maintenance, or extension of validated human healthspan, and no study in any system establishes telomerase mediation. At the claimed human scope there is no evidence at all; the level is carried by cell-culture and animal systems, which is what Γ describes." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\epitalon-telomerase\\consensus-browser-links.json", "sha256": "83c96e2919e70860e09a5ffb90af5d98b0f2daa6bb8b8b09e3f0cec095226f82" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\epitalon-telomerase\\consensus-browser.txt", "sha256": "daa27357fde4f5d327c518edc3caab8102e200550387e3853a3d5ca1a102ff88" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\epitalon-telomerase\\consensus-targeted-check.txt", "sha256": "27fe8179d2490051692715f6b29fefaf5046fbe79488fe2b4e6465674de8f757" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "epitalon-telomerase", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/epitalon-telomerase/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/epitalon-telomerase/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/epitalon-telomerase/consensus-browser-links.json" ], "reconciliation_existing": "Yes; 8 identifiers; selected Methods/Results passage and correction PMID 41240216 noted; corrected figures not re-quantified.", "primary_sources_matched": [ "11087911", "12937682", "14501183", "14523363", "15455129", "28241208", "40493162", "40908429" ], "limitations": "Targeted paper check covers specified cell lines/results only; correction means image-based quantitative claims need corrected-figure appraisal." } } }